Get started
Author

Jean Luc Canon

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
2013 · Jean-Yves Douillard, Kelly S. Oliner, et al. · New England Journal of Medicine · 2,306
PDF
Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group
2006 · Sylvie Giacchetti, Georg Bjarnason, et al. · Journal of Clinical Oncology · 245
PDF
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
2018 · P. Cottu, V. D'Hondt, et al. · Annals of Oncology · 175
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012 · E. Seront, S. Rottey, et al. · Annals of Oncology · 127
PDF
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
2012 · Martin Schuler, Ahmad Awada, et al. · Breast Cancer Research and Treatment · 90
PDF
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study
2023 · S. Joris, H. Denys, et al. · ESMO Open · 49
PDF
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
2011 · D. Rayson, T.M. Suter, et al. · Annals of Oncology · 42
PDF
Saccharomyces Cerevisiae Fungemia in a Head and Neck Cancer Patient: a Case Report and Review of the Literature
2004 · S. Henry, L. D’Hondt, et al. · Acta Clinica Belgica · 36
Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
2013 · Otto Metzger-Filho, Aurélie Catteau, et al. · PLoS ONE · 31
PDF
Flexible care in breast cancer
2021 · A. Wardley, J.-L. Canon, et al. · ESMO Open · 28
Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study
2003 · D Belpomme, I Krakowski, et al. · Gynecologic Oncology · 21
Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer
2019 · E. Van Cutsem, J. Machiels, et al. · Annals of Oncology · 14
PDF
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer
2018 · Mario Campone, Magali Lacroix-Triki, et al. · European Journal of Cancer · 11
BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies.
2009 · N. Harbeck, M. Schmidt, et al. · Cancer Research · 10
Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.
2009 · B. Coudert, M. Campone, et al. · Cancer Research · 10
1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)
2015 · D. Miles, D. Cameron, et al. · European Journal of Cancer · 7
SUCON Trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian Multicenter Phase II Randomized Trial in Her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy with Sunitinib after Objective Response to Taxane Chemotherapy.
2009 · H. Wildiers, C. Fontaine, et al. · Cancer Research · 5
An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+ Advanced Breast Cancer (ABC).
2009 · L. Dirix, J. Canon, et al. · Cancer Research · 5
[Efficiency of high-dose FEC chemotherapy for the mobilization of hematopoietic stem cells into peripheral blood].
1997 · L D'Hondt, M André, et al. · PubMed · 3
A phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
2018 · A. Devaux, J.-L. Canon, et al. · Annals of Oncology · 1
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study
2026 · Lore Decoster, Philippe Aftimos, et al. · JCO Precision Oncology
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
2023 · Elie Rassy, Thomas Filleron, et al. · Breast Cancer Research and Treatment
Renal Insufficiency in Cancer Patients : Results of the Birma Study
2008 · Hans Wildiers, Nicolas Janus, et al. · Digital Access to Libraries
Should sentinel node biopsy (SNB) be restricted to breast cancer-dedicated surgeons? A single institution prospective trial
2004 · J. P. Collart, M. Barette, et al. · Journal of Clinical Oncology
Works count: 24
Citation count: 3,216
H-index: 12
I10-index: 15
Year
Topic
Type